Atherosclerosis
Volume 209, Issue 1 , Pages 32-34 , March 2010

Apolipoprotein H: Its relevance to cardiovascular disease

  • M.A. Crook

      Affiliations

    • Dept of Clinical Biochemistry and Metabolic Medicine, University Hospital Lewisham, United Kingdom
    • Guy's Hospital, United Kingdom
    • St Thomas’ Hospital, United Kingdom
    • University of Greenwich, United Kingdom
    • Corresponding Author InformationCorrespondence address: Dept of Clinical Biochemistry, University Hospital Lewisham, London SE13 6LH, United Kingdom. Tel.: +44 208 333 3000.

Received 26 October 2009 ,Revised 15 November 2009 ,Accepted 15 November 2009.

References 

  1. Muller G, Biering A, Lux E, Richter V. Beta-2 glycoprotein I analysis in patients with hyperlipoproteinaemia, arteriosclerotic occlusive disease and diabetes mellitus. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1983;38:282–4 [English abstract].
  2. Lee NS, Brewer HB, Osborne JC. Beta-2 glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. J Biol Chem. 1983;258:4765–4770
  3. Polz E, Kostner GM. Binding of beta-2-glycoprotein-I to human-serum lipoproteins – distribution among density fractions. FEBS Lett. 1979;102:183–186
  4. Gambino R, Ruiu G, Pagano G, Cassader M. The binding of apolipoprotein H (beta2-blycoprotein I) to lipoproteins. Prostaglandins Other Lipid Mediat. 1999;57(July(5–6)):351–359
  5. Zahedi R, Summers L, Lumb P, Chik G, Crook M. The response of serum apolipoprotein H to an oral fat load. Ann Clin Biochem. 2004;41:330–334
  6. Agar Ç, de Groot PG, Levels HJ, Arnoud Marquart J, Meijers JCM. B2-Glycoprotein I is incorrectly named apolipoprotein H. J Thromb Haemost. 2009;7:235–236
  7. McNeil HP, Simpson RJ, Chesterman CN, Krillis SA. Antiphospholipid antibodies are directed at a complex antigen that includes a lipid binding inhibitor of coagulation: apolipoprotein H. Proc Natl Acad Sci. 1990;87:4120–4124
  8. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by beta-2-glycoprotein-I of the factor Xa generating activity of platelets. Thromb Haemost. 1994;71:526–527
  9. Nakaya Y, Schaefer EJ, Brewer HB. Activation of human post heparin lipoprotein lipase by apolipoprotein H. Biochim Biophys Res Commun. 1980;95:1168–1172
  10. Wurm H, Beubler E, Polz E, Holasek A, Kostner G. Studies on the possible function of beta-2-glycoprotein-I: influence in the triglyceride metabolism of the rat. Metabolism. 1982;31:484–486
  11. Nimpf J, Wurm H, Kostner GM. Interaction of beta-2-glycoprotein-I with human blood platelets: influence upon ADP induced aggregation. Thromb Haemost. 1985;54:397–401
  12. Valesini G, Shoenfeld Y. A new player in the antiphospholipid syndrome: the beta-2-glycoprotein cofactor. Autoimmunity. 1992;14:105–110
  13. Chonn A, Semple SC, Cullis PR. Beta2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of ‘non-self’ particles. J Biol Chem. 1995;270:25845–25849
  14. Thiagarajan P, Le A, Benedict CR. Beta(2)-glycoprotein I promotes the binding of anionic phospholipid vesicles by macrophages. Arterioscler Thromb Vasc Biol. 1999;19:2807–2811
  15. Ma K, Simantov R, Zhang JC, et al. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by Annexin II. J Biol Chem. 2000;275:15541–15548
  16. Matsuura E, Kobayashia K, Koikeb T, et al. Atherogenic autoantigen: oxidized LDL complexes with beta2-glycoprotein I. Immunobiology. 2003;207(1):17–22
  17. Lopez LR, Hurley BL, Simpson DF, Matsuura E. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann N Y Acad Sci. 2005;1051(June):97–103
  18. Matsuura E, Kobayashi K, Hurley BL, Lopez LR. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2006;15(7):478–483
  19. Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res. 2003;44(April(4)):716–726
  20. Lopez D, Garcia-Valladares I, Palafox-Sanchez CA, et al. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies to oxLig-1/beta2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol. 2004;121(March(3)):426–436
  21. George J, Afek A, Gilburd B, et al. Induction of early atherosclerosis in LDL receptor deficient mice immunized with beta 2 glycoprotein I. Circulation. 1998;15:1108–1115
  22. Afek A, George J, Shoenfeld Y, et al. Enhanced atherosclerosis in apoE deficient mice by immunization with b2-glycoprotein I. Pathobiology. 1999;67:19–25
  23. George J, Harats D, Gilburd B, et al. Adoptive transfer of b2-glycoprotein I (b2GPI)-reactive lymphocytes enhances early atherosclerosis in LDL receptor deficient mice. Circulation. 2000;102:1822–1827
  24. Visvanathan S, McNeil HP. Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. J Immunol. 1999;162:6919–6925
  25. Hattori N, Kuwana M, Kaburaki J, et al. T cells that are autoreactive to beta2- glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum. 2000;43:65–75
  26. Cassader M, Ruiu G, Gambino R, Veglia F, Pagano G. Apolipoprotein H concentrations in diabetic subjects: correlation with cholesterol concentrations. Metabolism. 1997;46:522–525
  27. Cavallo Perin P, Gruden G, Giunti S, et al. Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria. Nutr Metab Cardiovasc Dis. 2000;10(December(6)):311–314
  28. Crook M, Ch’ng SI, Lumb PJ. Serum apolipoprotein H and its relationship to lipids and other apolipoproteins in normal human men and women. Blood Coagulation Fibrinol. 1999;10:197–200
  29. Crook M, Ch’ng SI, Lumb P, Reid F. Serum apolipoprotein H and its relationship to blood pressure, serum lipids, fasting plasma glucose and insulin in normal individuals. Ann Clin Biochem. 2001;38(September(Pt 5)):494–498
  30. McNally T, Crook M, Mackie IJ, Isenberg DA, Machin SJ. Beta-2-glycoprotein-I antigen is increased in primary hyperlipidaemia. Br J Haem. 1993;88:424–426
  31. McNally T, Mackie IJ, Isenberg DA, Machin SJ. Immunoelectrophoresis and ELISA techniques for assay of plasma beta-2-glycoprotein-I and the influence of plasma lipid. Thromb Res. 1993;72:275–282
  32. Hoeg JM, Segal P, Gregg RE, et al. Characterisation of plasma lipids and lipoproteins in patients with beta-2-glycoprotein I deficiency. Atherosclerosis. 1985;55:25–34
  33. Sepehrnia B, Kamboh MI, Adams-Campbell LL, et al. Genetic studies of human apolipoproteins. Role of Apo H polymorphism in relation to serum lipoprotein concentrations. Hum Genet. 1989;82:118–122
  34. Eichner JE, Kuller LH, Kamboh MI, Ferrell RE. Phenotypic effects of apolipoprotein structural variation on lipid profiles. Apo H and quantitative lipid measures in the healthy women study. Genet Epidemiol. 1989;6:311–318
  35. Crews DE, Kamboh MI, Mancilha-Carvalho JJ, Kottke B. Population genetics of apolipoprotein A-4-E and H polymorphisms in Yanomami Indians of northwestern Brazil: associations with lipids, lipoproteins and carbohydrate metabolism. Hum Biol. 1993;65:211–224
  36. Saha N, Kamboh MI, Ahn YA, Tay JS, Ferrell RE. Apolipoprotein H polymorphism and serum lipoprotein and apolipoprotein concentrations in two Asian populations. Ethnicity Dis. 1993;3:250–254
  37. Kamboh MI, Wagenknecht DR, McIntyre JA. Heterogeneity of the apolipoprotein H3 allele and its role in affecting the binding of apolipoprotein H to anionic phospholipids. Hum Genet. 1995;95:385–388
  38. Cassader M, Ruiu G, Gambino R, et al. Influence of apolipoprotein H polymorphism on concentrations of triglycerides. Atherosclerosis. 1994;110:45–51
  39. Kamboh MI, Sanghera DK, Mehdi H, et al. A Single nucleotide polymorphisms in the coding region of the apolipoprotein H (beta2-glycoprotein I) gene and their correlation with the protein polymorphism, anti beta2glycoprotein I antibodies and cardiolipin binding: description of novel haplotypes and their evolution. Ann Hum Genet. 2004;68:285–299

PII: S0021-9150(09)00979-4

doi: 10.1016/j.atherosclerosis.2009.11.022

Atherosclerosis
Volume 209, Issue 1 , Pages 32-34 , March 2010

Article Tools

* Image Usage & Resolution